{"entity":{"id":"nct07605962","kind":"trial","name":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers","aka":[],"tldr":"A phase 1/2 trial of UI-102 in advanced solid tumours, run by United Immunity, co., Ltd., now recruiting.","summary":"Phase 1/2 Study of UI-102 in Selected Advanced Cancers is a phase 1/2 interventional study registered as NCT07605962 by United Immunity, co., Ltd., with 140 participants planned, started 2026-05-20 and due to reach its primary completion in 2030-03-31. Interventions recorded: UI-102.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07605962","url":"https://clinicaltrials.gov/study/NCT07605962"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07605962","phase":"1/2","setting":"A Phase I/II Open-Label, Dose Escalation, Dose Optimization, and Cohort Expansion Trial to Investigate the Safety, Pharmacokinetics and Pharmacodynamics of UI-102, a Novel Cholesteryl Pullulan (CHP) Nanoparticle-formulated TLR7/8 Agonist in Patients With Selected Locally Advanced and/or Metastatic Solid Tumors","sponsor":"United Immunity, co., Ltd.","enrolled":140,"outcomes":[]},"route":"/trials/nct07605962/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}]}}